 <h1>Advair Diskus Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>fluticasone / salmeterol</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about fluticasone / salmeterol. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Advair Diskus.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to fluticasone / salmeterol: inhalation aerosol liquid, inhalation disk, inhalation powder</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, fluticasone/salmeterol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking fluticasone/salmeterol:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blindness</li>
<li>blurred vision</li>
<li>burning, tingling, numbness, or pain in the hands, arms, feet, or legs</li>
<li>chills</li>
<li>cough</li>
<li>decreased vision</li>
<li>difficulty with breathing or swallowing</li>
<li>eye pain</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hives or welts, skin itching, rash, or redness</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>nausea</li>
<li>noisy breathing</li>
<li>painful or difficult urination</li>
<li>sensation of pins and needles</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>stabbing pain in the arms or legs</li>
<li>swollen glands</li>
<li>tearing</li>
<li>unusual bleeding or bruising</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Backache</li>
<li>bruising</li>
<li>darkening of the skin</li>
<li>decrease in height</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>facial hair growth in females</li>
<li>fainting</li>
<li>fast, slow, pounding, or irregular heartbeat or pulse</li>
<li>flushed, dry skin</li>
<li>fractures</li>
<li>fruit-like breath odor</li>
<li>full or round face, neck, or trunk</li>
<li>heavy bleeding</li>
<li>increased hunger</li>
<li>increased thirst or urination</li>
<li>irritability</li>
<li>large, flat, blue, or purplish patches in the skin</li>
<li>loss of sexual desire or ability</li>
<li>menstrual irregularities</li>
<li>mental depression</li>
<li>muscle pain or stiffness</li>
<li>muscle wasting</li>
<li>pain in the back, ribs, arms, or legs</li>
<li>pain in the joints</li>
<li>stomach pain</li>
<li>sweating</li>
<li>unexplained weight loss</li>
<li>unusual tiredness or weakness</li>
<li>weight gain</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking fluticasone/salmeterol:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Chest pain or tightness</li>
<li>confusion</li>
<li>decreased urine output</li>
<li>dry mouth</li>
<li>faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>general feeling of discomfort or illness</li>
<li>high blood pressure</li>
<li>loss of appetite</li>
<li>mood changes</li>
<li>nervousness</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>seizures</li>
<li>sudden sweating</li>
<li>tremors</li>
<li>trouble with sleeping</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of fluticasone / salmeterol may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>choking</li>
<li>congestion</li>
<li>dryness of the throat</li>
<li>high-pitched noise when breathing</li>
<li>hoarseness</li>
<li>runny nose</li>
<li>sneezing</li>
<li>trouble with swallowing</li>
<li>voice changes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cough-producing mucus</li>
<li>irritation or inflammation of the eye</li>
<li>muscle pain</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>sleep disorders</li>
<li>stuffy nose</li>
<li>white patches in the mouth or throat or on the tongue</li>
</ul><p>
<!-- end inhalation aerosol liquid, inhalation disk, inhalation powder --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fluticasone / salmeterol: inhalation aerosol, inhalation powder</i></p><h3>General</h3><p>The most common events that occurred more frequently were nasopharyngitis, upper respiratory tract infection, nasal congestion, back pain, sinusitis, dizziness, nausea, pneumonia, candidiasis, and dysphonia.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 21%)</p>
<p><b>Common</b> (1% to 10%): Migraine</p>
<p><b>Uncommon</b> (0.1% to 1%): Tremor</p>
<p><b>Postmarketing reports</b>: Paraesthesia, restlessness, compressed nerve syndrome, aphonia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>The incidence of pneumonia was higher in adult subjects with COPD older than 65 years compared with younger subjects with COPD (18% versus 14%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Upper respiratory tract infections (up to 27%), pharyngitis (up to 13%), nasopharyngitis</p>
<p><b>Common</b> (1% to 10%): Pneumonia, bronchitis, throat irritation, hoarseness, dysphonia, sinusitis, upper respiratory inflammation, viral respiratory infections, cough, rhinorrhea/postnasal drip, epistaxis, nasal congestion/blockage, laryngitis, unspecified oropharyngeal plaques, dryness of nose, lower respiratory signs and symptoms, lower respiratory infections, lower respiratory hemorrhage, congestion</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea</p>
<p><b>Rare</b> (less than 0.1%): Oropharyngeal angioedema, bronchospasm, paradoxical bronchospasm</p>
<p><b>Frequency not reported</b>: Nose, and throat infections, laryngitis, nasal sinus disorders, nasal sinus disorders</p>
<p><b>Postmarketing reports</b>: Paranasal sinus pain, rhinitis, throat soreness, tonsillitis, asthma, asthma exacerbation, chest congestion, chest tightness, tracheitis, wheezing, report of upper respiratory symptoms of laryngeal spasm, irritation, or swelling such as stridor or chocking<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations, tachycardia, arrhythmias, myocardial infarction, postoperative complications</p>
<p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, angina pectoris</p>
<p><b>Rare</b> (less than 0.1%): Cardiac arrhythmias (including supraventricular tachycardia and extrasystoles)</p>
<p><b>Frequency not reported</b>: Hematomas</p>
<p><b>Postmarketing reports</b>: Ventricular tachycardia, pallor<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Contusions, wounds, eczema, dermatitis, dermatosis</p>
<p><b>Frequency not reported</b>: Skin flakiness and acquired ichthyosis, disorders of sweat and sebum </p>
<p><b>Postmarketing reports</b>: Ecchymoses, photodermatitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Oral and throat candidiasis, nausea and vomiting, gastrointestinal discomfort and pain, dental discomfort and pain, hyposalivation, gastrointestinal infections, disorders of hard tissue of teeth, abdominal discomfort and pain, oral abnormalities, gastrointestinal discomfort and pain, viral gastrointestinal infections, diarrhea</p>
<p><b>Rare</b> (less than 0.1%): Esophageal candidiasis</p>
<p><b>Frequency not reported</b>: Oral lesions</p>
<p><b>Postmarketing reports</b>: Oral ulcerations, dyspepsia, xerostomia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Allergies and allergic reactions<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia, weight gain</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperglycemia</p>
<p><b>Frequency not reported</b>: Fluid retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Muscle cramps, traumatic fractures, arthralgia, myalgia, arthralgia, articular rheumatism, muscle spasms, musculoskeletal inflammation, bone and skeletal pain, muscle injuries, soft tissue injuries</p>
<p><b>Postmarketing reports</b>: Muscle stiffness, tightness and rigidity, bone and cartilage disorders, myositis, osteoporosis, fractures<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Allergic eye disorders, eye edema and swelling</p>
<p><b>Uncommon</b> (0.1% to 1%): Cataract</p>
<p><b>Rare</b> (less than 0.1%): Glaucoma</p>
<p><b>Frequency not reported</b>: Dry eyes, eye infections, keratitis, conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Candidiasis unspecified site, ear signs and symptoms, viral infections, bacterial infections, inflammation, bacterial reproductive infections</p>
<p><b>Rare</b> (less than 0.1%): Angioedema, facial angioedema</p>
<p><b>Frequency not reported</b>: Syncope, edema and swelling, dysmenorrhea, pain, unusual taste, lacerations</p>
<p><b>Postmarketing reports</b>: Ear ache, fever<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Cutaneous hypersensitivity reactions</p>
<p><b>Rare</b> (less than 0.1%): Anaphylactic reactions including anaphylactic shock<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Anxiety, sleep disorders</p>
<p><b>Rare</b> (less than 0.1%): Behavioral changes, including psychomotor hyperactivity and irritability (predominately in children) </p>
<p><b>Frequency not reported</b>: Depression, aggression (predominantly in children)</p>
<p><b>Postmarketing reports</b>: Agitation<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease bone mineral density</p>
<p><b>Frequency not reported</b>: Hypothyroidism</p>
<p><b>Postmarketing reports</b>: Hypercorticism<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Abnormal liver function tests<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Nathan RA, Seltzer JM, Kemp JP, Chervinsky P, Alexander WJ, Liddle R, Mills R "Safety of salmeterol in the maintenance treatment of asthma." Ann Allergy Asthma Immunol 75 (1995): 243-8</p><p id="ref_3">3. Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991): 895-912</p><p id="ref_4">4. "Product Information. Advair Diskus (fluticasone-salmeterol)" Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_5">5. "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_6">6. Lorentzen KA, Vanhelmond JLM, Bauer K, Langaker KE, Bonifazi F, Harris TAJ "Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr." Respir Med 90 (1996): 609-17</p><p id="ref_7">7. "Salmeterol." Med Lett Drugs Ther 36 (1994): 37-9</p><p id="ref_8">8. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_9">9. Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993): 1478-87</p><p id="ref_10">10. Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992): 342-5</p><p id="ref_11">11. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, et al "A comparison of salmeterol with albuterol in the treatment of mild-to- moderate asthma." N Engl J Med 327 (1992): 1420-5</p><p id="ref_12">12. "Product Information. Flovent (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_13">13. Mann RD, Kubota K, Pearce G, Wilton L "Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients." J Clin Epidemiol 49 (1996): 247-50</p><p id="ref_14">14. Kemp JP, Bierman CW, Cocchetto DM "Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring." Ann Allergy 70 (1993): 316-22</p><p id="ref_15">15. Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995): 868-75</p><p id="ref_16">16. Lopezguillen A, Marques L, Lopezllorente MT, Pastor E, Figueras A "Salmeterol-induced vertigo." Eur Respir J 7 (1994): 2089-90</p><p id="ref_17">17. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI "Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma." JAMA 271 (1994): 1412-6</p><p id="ref_18">18. Dottorini ML, Tantucci C, Peccini F, Grassi V, Sorbini CA "Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol." Int J Clin Pharmacol Ther 34 (1996): 438-43</p><p id="ref_19">19. Clark CE, Ferguson AD, Siddorn JA "Respiratory arrests in young asthmatics on salmeterol." Respir Med 87 (1993): 227-8</p><p id="ref_20">20. Wilkinson JR, Roberts JA, Bradding P, Holgate ST, Howarth PH "Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler." BMJ 305 (1992): 931-2</p><p id="ref_21">21. Ullman A, Svedmyr N "Salmeterol comparison with salbutamol in adult asthmatic patients." Thorax 43 (1988): 674-8</p><p id="ref_22">22. Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998): 1272-6</p><p id="ref_23">23. Britton MG, Earnshaw JS, Palmer JB "A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group [published erratum appears in Eur Respir J 1993;6(1):150]." Eur Respir J 5 (1992): 1062-7</p><p id="ref_24">24. Maconochie JG, Minton NA, Chilton JE, Keene ON "Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?" Br J Clin Pharmacol 37 (1994): 199-204</p><p id="ref_25">25. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J "Multicenter randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease." Lancet 351 (1998): 773-80</p><p id="ref_26">26. Holliday SM, Faulds D, Sorkin EM "Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma." Drugs 47 (1994): 318-31</p><p id="ref_27">27. Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993): 223-8</p><p id="ref_28">28. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992): 414-7</p><p id="ref_29">29. Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997): 722-7</p><p id="ref_30">30. Svedmyr N, Lofdahl CG "The use of beta(2)-adrenoceptor agonists in the treatment of bronchial asthma." Pharmacol Toxicol 78 (1996): 3-11</p><p id="ref_31">31. Booth H, Bish R, Walters J, Whitehead F, Walters EH "Salmeterol tachyphylaxis in steroid treated asthmatic subjects." Thorax 51 (1996): 1100-4</p><p id="ref_32">32. Hatton MQ, Allen MB, Mellor EJ, Cooke NJ "Salmeterol rash ." Lancet 337 (1991): 1169-70</p><p id="ref_33">33. Clark DJ, Lipworth BJ "Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients." Thorax 52 (1997): 55-8</p><p id="ref_34">34. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22</p><p id="ref_35">35. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997): 155-61</p><p id="ref_36">36. Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994): 521-5</p><p id="ref_37">37. Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999): 157-61</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Symbicort vs. Advair: How do they compare?</li>
<li>Is Wixela Inhub the same as Advair Diskus?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Advair Diskus (fluticasone / salmeterol)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>102 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: bronchodilator combinations</li>
<li>FDA Alerts (6)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Advair Diskus</li>
<li>Advair &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Advair Diskus &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Advair Diskus 100/50 &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li data-more-config-id="list-data-resources-consumer">... +2 more</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Advair HFA, AirDuo Respiclick, AirDuo Digihaler</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>COPD, Maintenance</li>
<li>Asthma, Maintenance</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fluticasone / salmeterol: inhalation aerosol, inhalation powder</i></p><h3>General</h3><p>The most common events that occurred more frequently were nasopharyngitis, upper respiratory tract infection, nasal congestion, back pain, sinusitis, dizziness, nausea, pneumonia, candidiasis, and dysphonia.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 21%)</p><p><b>Common</b> (1% to 10%): Migraine</p><p><b>Uncommon</b> (0.1% to 1%): Tremor</p><p><b>Postmarketing reports</b>: Paraesthesia, restlessness, compressed nerve syndrome, aphonia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>The incidence of pneumonia was higher in adult subjects with COPD older than 65 years compared with younger subjects with COPD (18% versus 14%).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Upper respiratory tract infections (up to 27%), pharyngitis (up to 13%), nasopharyngitis</p><p><b>Common</b> (1% to 10%): Pneumonia, bronchitis, throat irritation, hoarseness, dysphonia, sinusitis, upper respiratory inflammation, viral respiratory infections, cough, rhinorrhea/postnasal drip, epistaxis, nasal congestion/blockage, laryngitis, unspecified oropharyngeal plaques, dryness of nose, lower respiratory signs and symptoms, lower respiratory infections, lower respiratory hemorrhage, congestion</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea</p><p><b>Rare</b> (less than 0.1%): Oropharyngeal angioedema, bronchospasm, paradoxical bronchospasm</p><p><b>Frequency not reported</b>: Nose, and throat infections, laryngitis, nasal sinus disorders, nasal sinus disorders</p><p><b>Postmarketing reports</b>: Paranasal sinus pain, rhinitis, throat soreness, tonsillitis, asthma, asthma exacerbation, chest congestion, chest tightness, tracheitis, wheezing, report of upper respiratory symptoms of laryngeal spasm, irritation, or swelling such as stridor or chocking<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations, tachycardia, arrhythmias, myocardial infarction, postoperative complications</p><p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, angina pectoris</p><p><b>Rare</b> (less than 0.1%): Cardiac arrhythmias (including supraventricular tachycardia and extrasystoles)</p><p><b>Frequency not reported</b>: Hematomas</p><p><b>Postmarketing reports</b>: Ventricular tachycardia, pallor<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Contusions, wounds, eczema, dermatitis, dermatosis</p><p><b>Frequency not reported</b>: Skin flakiness and acquired ichthyosis, disorders of sweat and sebum </p><p><b>Postmarketing reports</b>: Ecchymoses, photodermatitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Oral and throat candidiasis, nausea and vomiting, gastrointestinal discomfort and pain, dental discomfort and pain, hyposalivation, gastrointestinal infections, disorders of hard tissue of teeth, abdominal discomfort and pain, oral abnormalities, gastrointestinal discomfort and pain, viral gastrointestinal infections, diarrhea</p><p><b>Rare</b> (less than 0.1%): Esophageal candidiasis</p><p><b>Frequency not reported</b>: Oral lesions</p><p><b>Postmarketing reports</b>: Oral ulcerations, dyspepsia, xerostomia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Allergies and allergic reactions<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia, weight gain</p><p><b>Uncommon</b> (0.1% to 1%): Hyperglycemia</p><p><b>Frequency not reported</b>: Fluid retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Muscle cramps, traumatic fractures, arthralgia, myalgia, arthralgia, articular rheumatism, muscle spasms, musculoskeletal inflammation, bone and skeletal pain, muscle injuries, soft tissue injuries</p><p><b>Postmarketing reports</b>: Muscle stiffness, tightness and rigidity, bone and cartilage disorders, myositis, osteoporosis, fractures<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Allergic eye disorders, eye edema and swelling</p><p><b>Uncommon</b> (0.1% to 1%): Cataract</p><p><b>Rare</b> (less than 0.1%): Glaucoma</p><p><b>Frequency not reported</b>: Dry eyes, eye infections, keratitis, conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Candidiasis unspecified site, ear signs and symptoms, viral infections, bacterial infections, inflammation, bacterial reproductive infections</p><p><b>Rare</b> (less than 0.1%): Angioedema, facial angioedema</p><p><b>Frequency not reported</b>: Syncope, edema and swelling, dysmenorrhea, pain, unusual taste, lacerations</p><p><b>Postmarketing reports</b>: Ear ache, fever<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Cutaneous hypersensitivity reactions</p><p><b>Rare</b> (less than 0.1%): Anaphylactic reactions including anaphylactic shock<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Anxiety, sleep disorders</p><p><b>Rare</b> (less than 0.1%): Behavioral changes, including psychomotor hyperactivity and irritability (predominately in children) </p><p><b>Frequency not reported</b>: Depression, aggression (predominantly in children)</p><p><b>Postmarketing reports</b>: Agitation<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease bone mineral density</p><p><b>Frequency not reported</b>: Hypothyroidism</p><p><b>Postmarketing reports</b>: Hypercorticism<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Abnormal liver function tests<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Nathan RA, Seltzer JM, Kemp JP, Chervinsky P, Alexander WJ, Liddle R, Mills R "Safety of salmeterol in the maintenance treatment of asthma." Ann Allergy Asthma Immunol 75 (1995): 243-8</p><p id="ref_3">3. Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991): 895-912</p><p id="ref_4">4. "Product Information. Advair Diskus (fluticasone-salmeterol)" Glaxo Wellcome, Research Triangle Pk, NC. </p><p id="ref_5">5. "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_6">6. Lorentzen KA, Vanhelmond JLM, Bauer K, Langaker KE, Bonifazi F, Harris TAJ "Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr." Respir Med 90 (1996): 609-17</p><p id="ref_7">7. "Salmeterol." Med Lett Drugs Ther 36 (1994): 37-9</p><p id="ref_8">8. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_9">9. Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993): 1478-87</p><p id="ref_10">10. Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992): 342-5</p><p id="ref_11">11. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, et al "A comparison of salmeterol with albuterol in the treatment of mild-to- moderate asthma." N Engl J Med 327 (1992): 1420-5</p><p id="ref_12">12. "Product Information. Flovent (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_13">13. Mann RD, Kubota K, Pearce G, Wilton L "Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients." J Clin Epidemiol 49 (1996): 247-50</p><p id="ref_14">14. Kemp JP, Bierman CW, Cocchetto DM "Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring." Ann Allergy 70 (1993): 316-22</p><p id="ref_15">15. Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995): 868-75</p><p id="ref_16">16. Lopezguillen A, Marques L, Lopezllorente MT, Pastor E, Figueras A "Salmeterol-induced vertigo." Eur Respir J 7 (1994): 2089-90</p><p id="ref_17">17. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI "Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma." JAMA 271 (1994): 1412-6</p><p id="ref_18">18. Dottorini ML, Tantucci C, Peccini F, Grassi V, Sorbini CA "Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol." Int J Clin Pharmacol Ther 34 (1996): 438-43</p><p id="ref_19">19. Clark CE, Ferguson AD, Siddorn JA "Respiratory arrests in young asthmatics on salmeterol." Respir Med 87 (1993): 227-8</p><p id="ref_20">20. Wilkinson JR, Roberts JA, Bradding P, Holgate ST, Howarth PH "Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler." BMJ 305 (1992): 931-2</p><p id="ref_21">21. Ullman A, Svedmyr N "Salmeterol comparison with salbutamol in adult asthmatic patients." Thorax 43 (1988): 674-8</p><p id="ref_22">22. Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998): 1272-6</p><p id="ref_23">23. Britton MG, Earnshaw JS, Palmer JB "A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group [published erratum appears in Eur Respir J 1993;6(1):150]." Eur Respir J 5 (1992): 1062-7</p><p id="ref_24">24. Maconochie JG, Minton NA, Chilton JE, Keene ON "Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?" Br J Clin Pharmacol 37 (1994): 199-204</p><p id="ref_25">25. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J "Multicenter randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease." Lancet 351 (1998): 773-80</p><p id="ref_26">26. Holliday SM, Faulds D, Sorkin EM "Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma." Drugs 47 (1994): 318-31</p><p id="ref_27">27. Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993): 223-8</p><p id="ref_28">28. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992): 414-7</p><p id="ref_29">29. Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997): 722-7</p><p id="ref_30">30. Svedmyr N, Lofdahl CG "The use of beta(2)-adrenoceptor agonists in the treatment of bronchial asthma." Pharmacol Toxicol 78 (1996): 3-11</p><p id="ref_31">31. Booth H, Bish R, Walters J, Whitehead F, Walters EH "Salmeterol tachyphylaxis in steroid treated asthmatic subjects." Thorax 51 (1996): 1100-4</p><p id="ref_32">32. Hatton MQ, Allen MB, Mellor EJ, Cooke NJ "Salmeterol rash ." Lancet 337 (1991): 1169-70</p><p id="ref_33">33. Clark DJ, Lipworth BJ "Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients." Thorax 52 (1997): 55-8</p><p id="ref_34">34. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22</p><p id="ref_35">35. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997): 155-61</p><p id="ref_36">36. Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994): 521-5</p><p id="ref_37">37. Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999): 157-61</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Symbicort vs. Advair: How do they compare?</li>
<li>Is Wixela Inhub the same as Advair Diskus?</li>
</ul><h2>More about Advair Diskus (fluticasone / salmeterol)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>102 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: bronchodilator combinations</li>
<li>FDA Alerts (6)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Advair Diskus</li>
<li>Advair &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Advair Diskus &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Advair Diskus 100/50 &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li data-more-config-id="list-data-resources-consumer">... +2 more</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>COPD, Maintenance</li>
<li>Asthma, Maintenance</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>